Menu menu
  • Flux RSS
  • Twitter
  • Facebook
  • Google Plus
  • LinkedIn
  • YouTube

2017

Enterome to Move its Research Laboratories to (...)

2017

ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, announced today that the Company is moving its research laboratories to Genopole, a leading biocluster dedicated to biotechnology and research in genomics and genetics. The new laboratories brings Enterome closer to its existing and potential new partners and provides opportunities to extend its scientific expertise and network to develop its business (...)

  • Lire la suite
  • Articles similaires

Pep-Therapy raises €1.2 M to advance its therapeutic

2017

PEP-Therapy, a biotechnology company, member of the Genopole biocluster, which develops innovative peptides as targeted therapies, has achieved a second fundraising of €1.2 million. This investment, made by the Quadrivium 1 seed fund and Dr Bernard Majoie, and based on the results obtained so far, will enable PEP-Therapy to continue the development of its products portfolio, especially to undertake the regulatory development of PEP-010 associated with its biomarker to foresee the efficacy of (...)

  • Lire la suite
  • Articles similaires

Illumina Opens First Commercial and Customer (...)

2017

Illumina, Inc. (NASDAQ:ILMN) today announced the opening of its Solutions Center on the Genopole Campus in Évry, near Paris. The leading-edge customer training center will offer demonstrations, instruction, and education in the latest genomics technologies from Illumina for up to 1,000 scientists a year, providing direct links to Illumina’s global network of facilities and in-house experts. The center will also accommodate Illumina’s first commercial office on the European continent to (...)

  • Lire la suite
  • Articles similaires